Posted by Michael Wonder on 28 Jun 2022
Adverum Biotechnologies granted Priority Medicines (PRIME) designation by EMA for ADVM-022 in wet AMD
24 June 2022 - Adverum Biotechnologies today announced that the EMA has granted ADVM-022 Priority Medicines (PRIME) designation for the treatment of wet age-related macular degeneration.
Adverum’s lead gene therapy candidate, ADVM-022 is a one time, intravitreal injection for the treatment of patients with wet age-related macular degeneration..
